Azacitidine and donor lymphocyte infusion for patients with relapsed acute myeloid leukemia and myelodysplastic syndromes after allogeneic hematopoietic stem cell transplantation: A meta-analysis

BACKGROUND: For patients with relapsed acute myeloid leukemia (AML) and myelodysplastic syndromes (MDS) after allogeneic hematopoietic stem cell transplantation (allo-HSCT), azacitidine with donor lymphocyte infusion (DLI) is a feasible option to perform a preemptive or salvage treatment. However, i...

Descripción completa

Detalles Bibliográficos
Autores principales: Li, Xuefeng, Wang, Wen, Zhang, Xin, Wu, Yu
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2022
Materias:
Oncology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389555/
https://www.ncbi.nlm.nih.gov/pubmed/35992868
http://dx.doi.org/10.3389/fonc.2022.949534

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9389555/
https://www.ncbi.nlm.nih.gov/pubmed/35992868
http://dx.doi.org/10.3389/fonc.2022.949534

Ejemplares similares